Chronic administration of myristic acid improves hyperglycaemia in the Nagoya–Shibata–Yasuda mouse model of congenital type 2 diabetes
- 560 Downloads
Previously, we demonstrated that myristic acid (14:0) increases levels of diacylglycerol kinase (DGK) δ, a key enzyme involved in type 2 diabetes exacerbation, and enhances glucose uptake in C2C12 myotube cells. Moreover, results from a population-based cohort study suggest that consumption of high-fat dairy products, which contain high amounts of myristic acid, is associated with a lower risk of developing type 2 diabetes. Taken together, we hypothesised that intake of myristic acid reduces type 2 diabetes risk in vivo. The aim of this study was to examine the glucose-lowering effect of myristic acid in Nagoya–Shibata–Yasuda (NSY) mice, a spontaneous model for studying obesity-related type 2 diabetes.
Male NSY mice were orally administered vehicle (n = 9), 300 mg/kg of myristic acid (n = 14) or 300 mg/kg of palmitic acid (16:0) (n = 9) every other day from 4 weeks of age. Glucose and insulin tolerance tests were performed at weeks 18, 24 and 30, and weeks 20 and 26, respectively. DGKδ levels were measured in skeletal muscle from 32–36-week-old NSY mice via western blot.
Chronic oral administration of myristic acid ameliorated glucose tolerance (24–28% decrease in blood glucose levels during glucose tolerance tests) and reduced insulin-responsive blood glucose levels (~20% decrease) in male NSY mice compared with vehicle and palmitic acid groups at 24–30 weeks of age (the age at which the severity of type 2 diabetes is exacerbated in NSY mice). Myristic acid also attenuated the increase in body weight seen in NSY mice. Furthermore, the fatty acid increased DGKδ levels (~1.6-fold) in skeletal muscle of NSY mice.
These results suggest that the chronic oral administration of myristic acid improves hyperglycaemia by decreasing insulin-responsive glucose levels and reducing body weight, and that the fatty acid accounts for the diabetes protective properties of high-fat dairy products. Myristic acid is a potential candidate for the prevention and treatment of type 2 diabetes mellitus and its related diseases.
KeywordsDairy fat Diabetes Diacylglycerol kinase Hyperglycaemia Myristic acid
Type 2 diabetes mellitus is a serious worldwide health issue [1, 2]. The characteristic features of type 2 diabetes include insulin resistance, glucose intolerance, hyperglycaemia and hyperinsulinaemia . It is known that the glucose-induced insulin resistance is associated with a long-term increase in the intracellular diacylglycerol mass .
Diacylglycerol is converted to phosphatidic acid by diacylglycerol kinase (DGK) [5, 6, 7, 8, 9]. Ten mammalian DGK isozymes are divided into five groups based on their primary structures. The type II DGK subfamily consists of δ [10, 11], η [12, 13] and κ  isoforms. In addition, alternative splice variants of DGKδ (δ1 and δ2)  and η (η1 and η2)  have been identified.
DGKδ is abundantly expressed in the skeletal muscle , which is a major target organ for insulin for glucose intake . Recently, Chibalin et al revealed that decreased levels of DGKδ are closely linked to high glucose-induced insulin resistance, which increases the severity of type 2 diabetes . Moreover, Miele et al demonstrated that acute exposure to high levels of glucose activated DGKδ in L6 skeletal muscle cells followed by attenuation of protein kinase C α activity and transactivation of the insulin receptor signal . Furthermore, we recently revealed that DGKδ preferentially phosphorylates palmitic acid (16:0)-containing diacylglycerol species such as 30:0-, 30:1-, 32:0-, 32:1-, 34:0- and 34:1-diacylglycerol (X:Y, where X is the total number of carbon atoms and Y is the total number of double bonds in both acyl chains of the lipids) derived from the phosphatidylcholine-specific phospholipase C pathway in high glucose-stimulated C2C12 myoblasts .
Because DGKδ is a key enzyme in the suppression of the pathogenesis of type 2 diabetes as described above, upregulation of DGKδ is important for prevention and treatment of the disease. Low-intensity endurance exercise increases the expression of DGKδ proteins in the skeletal muscles of individuals with type 2 diabetes [19, 20]. Interestingly, we recently demonstrated that myristic acid (14:0) substantially enhanced DGKδ content in C2C12 myotubes, whereas other fatty acids examined, such as lauric (12:0), palmitic (16:0) and stearic (18:0) acids, did not . Moreover, myristic acid significantly increased glucose uptake in C2C12 myotubes in a DGKδ-dependent manner .
Intriguingly, Ericson et al recently found that the consumption of high-fat dairy products was associated with a lower risk of developing diabetes in a population-based cohort study . It is noteworthy that dairy fat exceptionally contains a lot of myristic acid (approximately 12% of total fatty acids). Whereas, fat from the other sources, such as meat and plants, is generally less than 1% myristic acid. Indeed, a significant association between high intake of myristic acid and decreased type 2 diabetes risk was observed .
Therefore, we hypothesised that intake of myristic acid reduces type 2 diabetes risk in vivo. However, very little data concerning the effects of myristic acid on animal models of diabetes are available. In the present study, we examined the effect of myristic acid on diabetic risk factors, such as hyperglycaemia and insulin resistance, and DGKδ expression in Nagoya–Shibata–Yasuda (NSY) mice, which are widely used as a model for type 2 diabetes .
Myristic acid (14:0) and palmitic acid (16:0) in the form of NEFAs (more than 99% purity) were purchased from Wako Pure Chemical Industries (Osaka, Japan). BSA (fatty acid free) was obtained from Sigma-Aldrich (St Louis, MO, USA). The fatty acids were dispersed in 10% (wt/vol.) of BSA solution (vehicle) by sonication to a final concentration of 30 mg/ml.
Male NSY mice  (RBRC02946, RIKEN BioResource Center, Tokyo, Japan) were housed individually in stainless wire mesh cages in a room with a 12 h light/dark cycle and a constant temperature of 24 ± 1°C. Four-week-old male NSY mice were randomly divided into three groups using simple randomisation and orally administered either 10% (wt/vol.) of BSA (vehicle, n = 9), 300 mg/kg of palmitic acid (n = 9) or 300 mg/kg of myristic acid (n = 14). These dietary supplements were provided through a stomach tube each morning between 09:00 and 12:00 hours every other day for 28 weeks. All mice were allowed free access to water and chow (Oriental Yeast, Tokyo, Japan) during the experimental period. Calculated values of energy intakes from chow, BSA and fatty acid (myristic or palmitic acid) were: chow, ~63 kJ/day; BSA, ~0.33 kJ/day (approximately 0.5% of chow); fatty acid (myristic or palmitic acid), ~0.21 kJ/day (approximately 0.3% of chow). Therefore, the values from chow and BSA with and without fatty acid (myristic or palmitic acid) are ~63.09 kJ and ~63.30 kJ (difference: approximately 0.3%), respectively. Body weight was measured throughout the experiment (once every 4 weeks). Food intake (for 6 days) was measured at about 28 weeks of age. Group assignment and outcome assessment were blind to the investigator. This study was conducted in compliance with the National Institutes of Health: Guide for the Care and Use of Laboratory Animals, and the Institutional Animal Care and Use of the University of Chiba approved the protocol.
Glucose tolerance test
IPGTTs were performed at weeks 18, 24 and 30. Glucose (2 g/kg body weight, Wako Pure Chemical Industries) was administered to overnight (16 h)-fasted mice by i.p. injection. Blood samples were collected from the tail vein immediately preceding the glucose injection (0 min) and 30, 60, 90 and 120 min thereafter. Samples were then centrifuged at 1200 g for 25 min. Plasma glucose concentrations were measured using a glucose test kit (LabAssay Glucose, Wako Pure Chemical Industries). The AUC of the glucose (mmol/l × min) was also calculated from the glucose measurements at baseline (0 min), 30, 60, 90 and 120 min. Mice were excluded from the datasets if they were non-responsive: if they had a blood glucose levels <13.3 mmol/l 30 min after glucose injection.
Insulin tolerance test
Insulin tolerance tests were performed at weeks 20 and 26. Following 16 h of food deprivation, an insulin solution (0.5 U/kg body weight, Novolin, Novo Nordisk, Tokyo, Japan) was administered i.p. Blood samples were obtained from the tail vein immediately prior to the insulin administration (0 min), and 15, 30, 45 and 60 min later. Samples were then centrifuged at 1200g for 25 min. Plasma glucose concentrations were measured using a glucose test kit (LabAssay Glucose, Wako Pure Chemical Industries). The AUC of glucose (mmol/l × min) was also calculated from the glucose measurements at baseline (0 min), 15, 30, 45 and 60 min. Mice were excluded from the datasets if they were non-responsive: if blood glucose concentrations were not decreased 15 min after insulin injection.
Blood insulin concentration
Blood samples were obtained via the tail vein and then centrifuged at 1200g for 25 min. Plasma insulin concentrations were measured by an insulin ELISA kit (Mouse Insulin ELISA kit, Morinaga Institute of Biological Science, Tokyo, Japan).
Western blot analysis
Skeletal muscle from 32–36-week-old male NSY mice was homogenised in lysis buffer (50 mmol/l HEPES, pH 7.2, 150 mmol/l NaCl, 5 mmol/l MgCl2) containing 1 mmol/l phenylmethylsulfonyl fluoride, 20 μg/ml each of leupeptin, pepstatin, aprotinin and soybean trypsin inhibitor, and Complete EDTA-free Protease Inhibitor Cocktail (Roche Applied Science, Penzberg, Germany), and centrifuged at 3000g for 15 min. The protein concentration in the supernatant fractions was determined using a bicinchoninic acid protein assay kit (Thermo Scientific, Hudson, NH, USA). The tissue lysates (50 μg of protein) were separated on SDS-PAGE, and the separated proteins were transferred to a polyvinylidene difluoride membrane (Pall Life Sciences, Port Washington, NY, USA). The membrane was blocked with 5% skimmed milk (wt/vol.) and incubated with a rabbit anti-DGKδ polyclonal antibody (1:1000) (which was previously validated [10, 11]), overnight at 4°C. The immunoreactive bands were visualised using a peroxidase-conjugated goat anti-rabbit IgG antibody (1:20,000; Jackson ImmunoResearch Laboratories, West Grove, PA, USA) and the ECL Western Blotting Detection System (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) according to the manufacturers’ instructions. To control for background staining, the western blotting procedure was carried out on all membranes with the omission of the anti-DGKδ antibody (data not shown).
Data were analysed using PRISM version 5 (GraphPad Software, La Jolla, CA, USA) and expressed as mean ± SEM. Comparisons of two groups were performed using an unpaired Student’s t test. Comparisons of more than two groups were performed by one-way ANOVA followed by the Tukey’s post hoc test. The results were considered to be significant if the value of p was <0.05.
Effect of myristic acid on plasma glucose levels in NSY mice
Effect of myristic acid on insulin-responsive plasma glucose levels in NSY mice
Insulin levels prior to the glucose injection and 30 min thereafter in the male NSY mice at 24 weeks of age in GTTs (see Fig. 2c) were analysed. As shown in the electronic supplementary material (ESM) Fig. 1, the insulin levels prior to the glucose injection and 30 min thereafter were not significantly changed in the myristic acid group compared with the control and palmitic acid groups. The insulin levels 30 min after the glucose injection in the palmitic acid group were greater than in the control group.
Effect of myristic acid on body weight
We examined whether the organs were affected by the chronic administration of myristic acid. No obvious changes were observed in the dissected organs, including the skeletal muscle, liver, pancreas, stomach and small intestine, from the mice in the myristic acid group (data not shown).
Effect of myristic acid on the expression level of DGKδ in skeletal muscle
Risk factors for type 2 diabetes mellitus include hyperglycaemia and insulin resistance. Our results demonstrate that chronic oral administration of myristic acid improves hyperglycaemia and insulin resistance in spontaneously diabetic male NSY mice.
Ericson et al. recently reported that the consumption of high-fat dairy products was associated with a lower risk of developing diabetes in a population-based cohort study . Dairy fat contains an exceptionally large proportion of myristic acid (approximately 12% of total fatty acids). Whereas, fat from the other sources, such as meat and plants, is generally less than 1% myristic acid. Indeed, the authors observed that a high intake of myristic acid (14:0) was significantly associated with a decreased risk of type 2 diabetes, whereas intake of palmitic acid (16:0) was not . The administration of 300 mg/kg of myristic acid into a mouse every other day is equivalent to an intake of 9 g of the fatty acid every day for a 60 kg person. This amount is easily taken by people who willingly eat high-fat dairy products on a daily basis. Therefore, it is possible that myristic acid contributes to the favourable effect of high-fat dairy products on the development of diabetes. Our results support the observations by Ericson et al . However, experimental studies in healthy mice and humans are still missing. This data from mouse models of diabetes should be interpreted carefully.
The administration of myristic acid increased DGKδ levels (Fig. 6b). DGKδ has been reported to positively regulate insulin receptor signalling [16, 17]. Therefore, the favourable effects of myristic acid on hyperglycaemia and insulin-responsive blood glucose levels may be mediated at least in part by upregulation of the DGKδ in skeletal muscle. However, identifying the detailed mechanisms of the favourable effects in vivo was beyond the scope of this study. Studies to investigate changes in diacylglycerol and phosphatidic acid levels and how they are involved in the activation of conventional/novel and atypical protein kinase C in skeletal muscle and the liver are warranted. Preliminary results (data not shown) have indicated that diacylglycerol and phosphatidic acid levels are regulated in a complex manner.
Palmitic acid (16:0) slightly reduced blood glucose concentration in a GTT (Fig. 2). However, the effects were weaker and appeared later compared with myristic acid. Palmitoleic acid (16:1, n−7) has also been reported to be effective on hyperglycaemia in a diabetic mouse model (KK-Ay mice) . Neither palmitic nor palmitoleic acid increase DGKδ expression [21, 22]. Therefore, these fatty acids probably improve hyperglycaemia in diabetic mice through a different pathway to myristic acid.
Ueda et al reported that the fasting plasma glucose levels of the NSY mice were increased from 24 to 32 weeks of age [24, 25]. We obtained essentially the same result (Fig. 1). In addition, the maximum plasma glucose levels of the NSY mice in a GTT were longitudinally increased from ~22.2 to ~27.8 mmol/l from 18 to 30 weeks of age (Fig. 2). Moreover, the number of diabetic NSY mice in which the plasma glucose level was >11.1 mmol/l after 120 min of glucose administration in a GTT was also increased from 18 to 30 weeks of age (Fig. 3). These results suggest that in NSY mice the severity of hyperglycaemia is exacerbated at 24–30 weeks of age. Myristic acid began to show its effects on hyperglycaemia and insulin resistance from 24 weeks of age (Figs 1, 2, 3), suggesting that the fatty acid prevents hyperglycaemia at the exacerbation stage in male NSY mice.
An insulin tolerance test showed that plasma glucose concentrations in the myristic acid group at 26 weeks of age, but not at 20 weeks, were lower than in the palmitic acid and control groups (Fig. 4). The results suggest that myristic acid decreases insulin-responsive blood glucose levels at the point of diabetes exacerbation in NSY mice, as with the effect on hyperglycaemia described above. Myristic acid did not decrease plasma insulin levels in the NSY mice (ESM Fig. 1). Ueda et al reported that plasma insulin levels were not greatly increased in NSY mice even when impaired glucose tolerance was detected . Therefore, it is likely that myristic acid primarily affects insulin receptor signalling rather than insulin secretion in NSY mice. We previously demonstrated that, in addition to insulin-dependent glucose uptake, myristic acid enhanced insulin-independent glucose uptake in C2C12 mouse myotubes . Therefore, myristic acid might enhance both insulin-dependent and -independent glucose uptake in type 2 diabetic mice.
There is growing evidence that excess body weight is associated with type 2 diabetes [27, 28]. The administration of myristic acid to NSY mice reduced body weight and fat gain (Fig. 5 and ESM Fig. 2), which may in turn improve lipid and glucose metabolism. Myristic acid treatment did not affect food intake (Fig. 5b), suggesting that certain metabolic changes were induced by myristic acid. However, food intake was only measured for a short period in the present study. Therefore, although it seems unlikely, we cannot exclude the possibility that the differences in body weight are due to unmeasured differences in food intake.
Cumulative evidence supports that fatty acids are involved in type 2 diabetes mellitus. Many reports have shown that fatty acids with different degrees of saturation affect insulin sensitivity and lipid/glucose metabolism differently. Although saturated fatty acids generally cause insulin resistance, unsaturated fatty acids ameliorate the pathology associated with diabetes [29, 30]. NEFAs (especially saturated fatty acids) generally attenuate insulin sensitivity and glucose uptake in skeletal muscle [31, 32]. However, the detailed effects of fatty acid carbon length on hyperglycaemia and insulin resistance have not been thoroughly investigated. In the present study, we have demonstrated that myristic acid (14:0), but not palmitic acid (16:0), strongly improves hyperglycaemia and insulin resistance.
In conclusion, the chronic oral administration of myristic acid to NSY mice markedly ameliorated their diabetic condition. Hyperglycaemia, insulin resistance and body weight were all reduced in response to myristic acid. Therefore, myristic acid is a potential candidate for the prevention and treatment of type 2 diabetes mellitus and related diseases. However, the detailed mechanisms of its favourable effects in vivo are still poorly understood. Moreover, it is still not clear what effects myristic acid has in normal mice, such as high-fat-fed wild-type mice. Further studies are needed to clarify these issues.
We acknowledge D. Takahashi (Graduate School of Science, Chiba University, Chiba, Japan) for a critical review of the manuscript.
The datasets generated and/or analysed during the current study are available from the corresponding author on reasonable request.
This work was supported in part by grants from MEXT/JSPS KAKENHI grant numbers 17H03650 (Grant-in-Aid for Scientific Research (B)), 22370047 (Grant-in-Aid for Scientific Research (B)), 23116505 (Grant-in-Aid for Scientific Research on Innovative Areas), 25116704 (Grant-in-Aid for Scientific Research on Innovative Areas), 26291017 (Grant-in-Aid for Scientific Research (B)) and 15K14470 (Grant-in-Aid for Challenging Exploratory Research); the Japan Science and Technology Agency (AS221Z00794F, AS231Z00139G, AS251Z01788Q and AS2621643Q); the Naito Foundation; the Hamaguchi Foundation for the Advancement of Biochemistry; the Daiichi-Sankyo Foundation of Life Science; the Terumo Life Science Foundation; the Futaba Electronic Memorial Foundation; the Daiwa Securities Health Foundation; the Ono Medical Research Foundation; the Japan Foundation for Applied Enzymology; the Food Science Institute Foundation; the Skylark Food Science Institute; the Asahi Group Foundation; and the Japan Milk Academic Alliance (FS).
Duality of interest
The authors declare that they have no conflicts of interest regarding the content of this article.
TT, KI, CM and YW designed and performed the experiments, and analysed the data. FS conceived and coordinated the study and wrote the paper. All authors drafted the article and revised it critically for important intellectual content and provided final approval of the version to be published. FS is responsible for the integrity of the work as a whole.